TriangleNCT00621244 · OUTCOME
Highest Percent Change in Fetal Hemoglobin From Baseline in Arm 1 (MWF Every Week)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Percent Change
- Interval / dispersion
- Standard Deviation
- Time frame
- Post dose to pre-dose (up to 3.5 years)
What was measured
All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days \[96 hours\]))
Analysis population: Full Analysis Set (with available samples for analysis)
Groups in this outcome
Arm 1, Group X (20 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group x (30 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group X (40 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group X (60 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group X (80 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group Y (20 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group Y (30 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group Y (40mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
Arm 1, Group Y (60 mg)
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
| Group | Source count |
|---|---|
| Arm 1, Group X (20 mg) | 8 |
| Arm 1, Group x (30 mg) | 4 |
| Arm 1, Group X (40 mg) | 7 |
| Arm 1, Group X (60 mg) | 21 |
| Arm 1, Group X (80 mg) | 8 |
| Arm 1, Group Y (20 mg) | 1 |
| Arm 1, Group Y (30 mg) | 4 |
| Arm 1, Group Y (40mg) | 16 |
| Arm 1, Group Y (60 mg) | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm 1, Group X (20 mg) | 56.6 | 97.26 | Not reported | Not reported | Not reported |
| Arm 1, Group x (30 mg) | 22.5 | 45 | Not reported | Not reported | Not reported |
| Arm 1, Group X (40 mg) | 63.2 | 87.21 | Not reported | Not reported | Not reported |
| Arm 1, Group X (60 mg) | 591.4 | 2438.34 | Not reported | Not reported | Not reported |
| Arm 1, Group X (80 mg) | 31 | 70.04 | Not reported | Not reported | Not reported |
| Arm 1, Group Y (20 mg) | 66.7 | NA | Not reported | Not reported | there was only 1 patient in the group, the standard deviation using the common Bessel correction cannot be derived. |
| Arm 1, Group Y (30 mg) | 150.0 | 125.59 | Not reported | Not reported | Not reported |
| Arm 1, Group Y (40mg) | 196.3 | 193.25 | Not reported | Not reported | Not reported |
| Arm 1, Group Y (60 mg) | 1998.5 | 4250.04 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 97.26
- value
- 56.6
- group Id
- OG001
- spread
- 45
- value
- 22.5
- group Id
- OG002
- spread
- 87.21
- value
- 63.2
- group Id
- OG003
- spread
- 2438.34
- value
- 591.4
- group Id
- OG004
- spread
- 70.04
- value
- 31
- comment
- there was only 1 patient in the group, the standard deviation using the common Bessel correction cannot be derived.
- group Id
- OG005
- spread
- NA
- value
- 66.7
- group Id
- OG006
- spread
- 125.59
- value
- 150.0
- group Id
- OG007
- spread
- 193.25
- value
- 196.3
- group Id
- OG008
- spread
- 4250.04
- value
- 1998.5
- denoms
- counts
- group Id
- OG000
- value
- 8
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 21
- group Id
- OG004
- value
- 8
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 16
- group Id
- OG008
- value
- 5
- units
- Participants
- description
- All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days \[96 hours\]))
- dispersion Type
- Standard Deviation
- groups
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG000
- title
- Arm 1, Group X (20 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG001
- title
- Arm 1, Group x (30 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG002
- title
- Arm 1, Group X (40 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG003
- title
- Arm 1, Group X (60 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG004
- title
- Arm 1, Group X (80 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG005
- title
- Arm 1, Group Y (20 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG006
- title
- Arm 1, Group Y (30 mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG007
- title
- Arm 1, Group Y (40mg)
- description
- Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week.
- id
- OG008
- title
- Arm 1, Group Y (60 mg)
- param Type
- MEAN
- population Description
- Full Analysis Set (with available samples for analysis)
- reporting Status
- POSTED
- time Frame
- Post dose to pre-dose (up to 3.5 years)
- title
- Highest Percent Change in Fetal Hemoglobin From Baseline in Arm 1 (MWF Every Week)
- type
- SECONDARY
- unit Of Measure
- Percent Change
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice